| Gene symbol | RPGR | Synonyms | COD1, CORDX1, CRD, PCDX, RP15, RP3, XLRP3, orf15 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xp11.4 | dbXrefs | |
| Description | retinitis pigmentosa GTPase regulator | ||||
| GTO ID | GTC3454 |
| Trial ID | NCT05874310 |
| Disease | Retinitis Pigmentosa |
| Altered gene | RPGR |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | FT-002 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa. |
| Year | 2023 |
| Country | China |
| Company sponsor | Frontera Therapeutics |
| Other ID(s) | FT002RP-1 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||